Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Homologous boost-National Taiwan University Hospital-COVID-19
- Development stage
- Approved
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Homologous boost-National Taiwan University Hospital-COVID-19 refers to a specific vaccination regimen evaluated in a Phase 4 clinical trial (NCT05007938) conducted by National Taiwan University Hospital. This regimen consists of a homologous prime-boost schedule using two doses of the mRNA-1273 (Moderna) vaccine. mRNA-1273 is a lipid nanoparticle-encapsulated mRNA vaccine that encodes the prefusion-stabilized spike protein of the SARS-CoV-2 virus. In the context of this study, the homologous mRNA-1273 schedule served as the control arm to evaluate the safety and immunogenicity of a heterologous booster regimen where a second dose of the protein subunit vaccine MVC-COV1901 was administered to adults who had previously received a single dose of mRNA-1273.
- Brand names
- Spikevax
- Other names
- Moderna COVID-19 Vaccineelasomeran
02
Targets
ACE2 (Angiotensin-converting enzyme 2)PSMB9 (Immunoproteasome subunit beta type-1i)B-cell receptors and antibodies specific for SARS-CoV-2 spike80S ribosome (Ribosome and ribosomal components)Innate immune RNA sensorsT-cell receptor specific for SARS-CoV-2 spike peptide-MHC complex (Spike-specific TCR)SARS-CoV-2 spike
Beyond the preview
Go deeper on Homologous boost-National Taiwan University Hospital-COVID-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Homologous boost-National Taiwan University Hospital-COVID-19.